Back to news

Purple Biotech Reports Third Quarter 2026 Financial Results and Provides Business Update

Globe Newswire•17/11/2026•07:55 ET
1

Key Highlights

  • ➤Cash $5.1 million, expected to fund operations through late-2027
  • ➤IM1240 IND submission planned during 2027, followed by first-in-human study
  • ➤IM1240 data selected for plenary oral presentation at EORTC-NCI-AACR Symposium
  • ➤U.S. patent granted covering CAPTN-3 tri-specific antibody constructs and methods
  • ➤Third-quarter net loss $1.0 million, down from $1.3 million year over year

Expert Statements

Isaac Israel, Interim Chief Executive Officer of Purple Biotech

“Purple Biotech today has a focused set of assets: the CAPTN-3 platform, its lead candidate IM1240, and a second candidate, IM1305. That foundation was built under Gil Efron as Chief Executive Officer.”

Isaac Israel, Interim Chief Executive Officer of Purple Biotech

“My first priority is to bring IM1240 into a first-in-human study. What we believe sets CAPTN-3 apart is that its antibodies are designed to engage both T cells and NK cells against the tumor and to confine that activity to the tumor microenvironment. Many patients with advanced solid tumors do not respond to today’s immunotherapies, or relapse after an initial response. Those are the patients we are working for.”

Isaac Israel, Interim Chief Executive Officer of Purple Biotech

“Alongside our preparation of an IND application for IM1240, we continue to advance additional work on the platform. IM1240 data in treatment-resistant human tumor models will be presented this week in a plenary session at the EORTC-NCI-AACR Symposium. Separately, we plan to report new preclinical data on IM1305, our second candidate, in the near term.”

Isaac Israel, Interim Chief Executive Officer of Purple Biotech

“As we previously reported, we are also bringing artificial intelligence into our antibody development. In our collaboration with Converge Bio, we are applying generative artificial intelligence to the design and optimization of our tri-specific antibodies, and we expect to provide an update on that work shortly. We believe artificial intelligence has the potential to make significant parts of drug development more efficient, and we intend to extend its use across the Company, with attention to data security and privacy.”

IM1240 tri-specific antibody (capped-CD3x5T4xNKG2A): Investigational New Drug (IND) application submission planned during 2027, followed by a first-in-human study

IM1240 data to be presented in a plenary oral session at the 38th EORTC-NCI-AACR Symposium on November 20, 2026

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in